公开(公告)号：US10131653B2

公开(公告)日：2018-11-20

申请号：US15568644

申请日：2016-04-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taku Kamei ,  Yasuyoshi Arikawa ,  Tomohiro Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Takashi Miki ,  Jinichi Yonemori ,  Yuya Oguro ,  Takahiro Sugimoto ,  Masaki Seto ,  Goushi Nishida ,  Makoto Kamata ,  Hiroshi Imoto

IPC: C07D413/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14 ,  A61P25/20 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61K31/553

Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10214508B2

公开(公告)日：2019-02-26

申请号：US15318552

申请日：2015-06-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Ryosuke Arai

IPC: C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  C07D213/81 ,  C07D405/12

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

公开(公告)号：US08993598B2

公开(公告)日：2015-03-31

申请号：US14043018

申请日：2013-10-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Haruyuki Nishida ,  Yasuyoshi Arikawa ,  Ikuo Fujimori

IPC: A61K31/4439 ,  A61K31/444 ,  C07D401/14

CPC classification number: A61K31/444 ,  C07D401/14

Abstract: The present invention relates to a compound represented by the formula: wherein A is pyridyl group having at least one substituent wherein R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, R4 and R6 are each a hydrogen atom, a halogen atom or a C1-6 alkyl group optionally substituted by halogen, R5 is a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, and R7 is a hydrogen atom or a C1-6 alkyl group optionally substituted by halogen or a salt thereof, or a pharmaceutical composition containing the same.

公开(公告)号：US10208046B2

公开(公告)日：2019-02-19

申请号：US15311025

申请日：2015-05-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Kenichiro Shimokawa ,  Takuto Kojima ,  Hiroki Sakamoto ,  Ikuo Fujimori ,  Minoru Nakamura ,  Masami Yamada ,  Masataka Murakami ,  Makoto Kamata ,  Shinkichi Suzuki

IPC: A61K31/437 ,  C07D487/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/519 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.

公开(公告)号：US09777005B2

公开(公告)日：2017-10-03

申请号：US14443598

申请日：2013-11-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Shinkichi Suzuki ,  Masami Yamada ,  Makoto Kamata ,  Takuto Kojima ,  Ikuo Fujimori ,  Kenichiro Shimokawa

IPC: C07D221/02 ,  A61K31/44 ,  C07D487/04 ,  C07D401/14 ,  C07D405/14 ,  C07D401/06 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/14 ,  C07D209/46 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D209/46 ,  C07D401/06 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/14 ,  C07D519/00

Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa═ or —N═; X2 is —CRb═ or —N═; X3 is —CRc= or —N═; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.

公开(公告)号：US09133129B2

公开(公告)日：2015-09-15

申请号：US14353622

申请日：2012-10-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tohru Yamashita ,  Takuya Fujimoto ,  Ryo Mizojiri ,  Kazuko Yonemori ,  Hideki Hirose ,  Zenichi Ikeda ,  Ikuo Fujimori ,  Kyoko Toyofuku ,  Tsuneo Yasuma ,  Nobuyuki Matsunaga

IPC: A61K31/437 ,  C07D471/04 ,  C07D231/56 ,  A61K31/343 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4439 ,  C07D413/04 ,  C07D498/04 ,  C07D307/80 ,  C07D235/18 ,  C07D263/57 ,  C07D513/04

CPC classification number: C07D231/56 ,  A61K31/343 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4439 ,  C07D235/18 ,  C07D263/57 ,  C07D307/80 ,  C07D413/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US20220017530A1

公开(公告)日：2022-01-20

申请号：US17475733

申请日：2021-09-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Kazuaki Takami ,  Masaki Seto ,  Shinobu Sasaki ,  Haruhi Ando ,  Masaki Ogino ,  Tomoko Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Yasuhiro Tsukimi ,  Masami Yamada ,  Kenichiro Shimokawa ,  Takeshi Wakabayashi ,  Masataka Murakami ,  Makoto Fushimi ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Tomohiro Ohashi ,  Hideo Suzuki ,  Hironobu Maezaki ,  Ayumu Sato ,  Yasutomi Asano ,  Steve Swann

IPC: C07D491/048 ,  A61P1/10 ,  A61K31/4355

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20140243310A1

公开(公告)日：2014-08-28

申请号：US14353622

申请日：2012-10-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tohru Yamashita ,  Takuya Fujimoto ,  Ryo Mizojiri ,  Kazuko Yonemori ,  Hideki Hirose ,  Zenichi Ikeda ,  Ikuo Fujimori ,  Kyoko Toyofuku ,  Tsuneo Yasuma ,  Nobuyuki Matsunaga

IPC: C07D231/56 ,  C07D498/04 ,  C07D307/80 ,  C07D413/04 ,  C07D263/57 ,  C07D235/18

CPC classification number: C07D231/56 ,  A61K31/343 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4439 ,  C07D235/18 ,  C07D263/57 ,  C07D307/80 ,  C07D413/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US11236099B2

公开(公告)日：2022-02-01

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki Takami ,  Masaki Seto ,  Shinobu Sasaki ,  Haruhi Ando ,  Masaki Ogino ,  Tomoko Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Yasuhiro Tsukimi ,  Masami Yamada ,  Kenichiro Shimokawa ,  Takeshi Wakabayashi ,  Masataka Murakami ,  Makoto Fushimi ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Tomohiro Ohashi ,  Hideo Suzuki ,  Hironobu Maezaki ,  Ayumu Sato ,  Yasutomi Asano ,  Steve Swann

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09732086B2

公开(公告)日：2017-08-15

申请号：US14443598

申请日：2013-11-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Shinkichi Suzuki ,  Masami Yamada ,  Makoto Kamata ,  Takuto Kojima ,  Ikuo Fujimori ,  Kenichiro Shimokawa

IPC: C07D221/02 ,  A61K31/44 ,  C07D487/04 ,  C07D401/14 ,  C07D405/14 ,  C07D401/06 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/14 ,  C07D209/46 ,  C07D519/00

Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa═ or —N═; X2 is —CRb═ or —N═; X3 is —CRc= or —N═; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.